Does Horizon Blue Cross Blue Shield of New Jersey Cover Eliquis?

What Is Eliquis and Why Is Coverage Important?

Eliquis (apixaban) is a direct oral anticoagulant (DOAC) approved by the FDA for stroke prevention in non-valvular atrial fibrillation (NVAF), treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prophylaxis of DVT following hip or knee replacement surgery. [1] Coverage matters because retail cash prices without insurance or a copay card typically exceed $600 per 30-day supply, making unassisted out-of-pocket costs prohibitive for patients who need long-term anticoagulation.

Apixaban works by selectively inhibiting free and clot-bound Factor Xa and prothrombinase activity, reducing thrombin generation without requiring routine INR monitoring. [2] This distinguishes it from warfarin, which requires frequent blood draws and dietary adjustments, and explains why guidelines from the American Heart Association now prefer DOACs over vitamin K antagonists for NVAF in most patients. [3]

The ARISTOTLE trial (N=18,201) demonstrated that apixaban reduced stroke or systemic embolism by 21% relative to warfarin (1.27% vs. 1.60% per year; P<0.001) and cut major bleeding by 31% (2.13% vs. 3.09% per year; P<0.001). [4] Those are not incremental gains. For patients who cannot afford their prescription, the clinical consequences of gaps in anticoagulation therapy can include stroke, PE, or recurrent DVT.

The 2023 ACC/AHA/ACCP/HRS Atrial Fibrillation Guideline gives apixaban a Class I recommendation for stroke prevention in NVAF patients with a CHA2DS2-VASc score of 2 or greater in men and 3 or greater in women. [3] Understanding how Horizon BCBS NJ treats apixaban on its formularies is therefore not merely a billing question; it directly affects medication adherence and patient safety.

How Horizon BCBS NJ Places Eliquis on Its Formulary

Horizon Blue Cross Blue Shield of New Jersey manages drug coverage through its Pharmacy Benefit Manager (PBM), and formulary tiers vary by plan type. On most standard commercial PPO and HMO plans, Eliquis sits at Tier 3 (preferred brand) or Tier 4 (non-preferred brand). [5] Medicare Advantage plans administered by Horizon generally place apixaban at Tier 3 under Part D, subject to the standard deductible phase, initial coverage phase, and catastrophic coverage thresholds set annually by CMS. [6]

Tier placement has a direct dollar impact. A Tier 3 copay under a typical Horizon commercial plan runs $50 to $100 per 30-day fill, while a Tier 4 placement can push cost-sharing to 30% to 50% coinsurance, potentially hundreds of dollars monthly. Under Medicare Part D in 2025, the out-of-pocket cap is $2,000 per year for all covered drugs combined following the Inflation Reduction Act changes, which provides meaningful protection for seniors on long-term apixaban therapy. [6]

The specific tier for a member's plan appears in that plan's Summary of Benefits and Coverage (SBC) and the online formulary lookup tool on the Horizon BCBS NJ member portal. Because Horizon administers dozens of distinct plan designs sold to New Jersey employers and individuals, the tier for any given member may differ from the general patterns described here. Checking the formulary tool with the exact plan ID is the only way to confirm current tier and cost-sharing.

Formulary status also changes annually during the October to January plan year transition. Eliquis has historically remained covered but has shifted between preferred and non-preferred brand tiers on some plans as contract negotiations between Horizon, its PBM, and Bristol-Myers Squibb/Pfizer evolve. [5]

Prior Authorization Requirements for Eliquis Under Horizon BCBS NJ

Most Horizon BCBS NJ plans require prior authorization (PA) before covering Eliquis. The PA criteria typically ask prescribers to document the FDA-approved indication (NVAF, DVT/PE treatment, surgical prophylaxis), confirm that the diagnosis meets clinical thresholds (for example, a documented CHA2DS2-VASc score for NVAF), and in some cases demonstrate that alternative anticoagulants have been considered or trialed. [7]

PA approval periods are usually 12 months for chronic indications like NVAF, with annual reauthorization required. For acute indications such as DVT/PE treatment, the initial approval may cover only the acute treatment phase (6 months), after which a new PA is needed to continue secondary prevention dosing. Prescribers should use the CMS-1500 form or Horizon's electronic PA portal and attach relevant diagnostic documentation, including ECG confirmation of atrial fibrillation, imaging reports for DVT/PE, or operative notes for surgical prophylaxis.

Patients denied PA have the right to file an internal appeal within 60 days of denial under New Jersey state insurance regulations. [8] External appeals to an Independent Utilization Review Organization (IURO) are available under the New Jersey External Appeal Act if the internal appeal is unsuccessful. [8] The New Jersey Department of Banking and Insurance (DOBI) oversees this process, and patients can file a complaint with DOBI if they believe an appeal was improperly handled.

Step Therapy and the Warfarin Requirement

Several Horizon plan designs impose step therapy for Eliquis, requiring documented use or clinical justification for bypassing warfarin before apixaban will be approved. [9] This policy reflects the cost difference between generic warfarin (often under $10/month) and branded apixaban, but it conflicts with guideline recommendations in certain clinical contexts.

The 2023 ACC/AHA/ACCP/HRS guideline explicitly states: "For patients with AF who require anticoagulation, DOACs are recommended over warfarin when there are no contraindications." [3] A prescriber can use this guideline language as clinical justification to request a step therapy exception, arguing that warfarin is not an appropriate first-line agent for the specific patient. Valid clinical reasons for bypassing warfarin include:

• Documented labile INR history on prior warfarin therapy (time in therapeutic range below 60%)
• Dietary or drug interactions making INR control difficult to achieve
• Occupational or lifestyle factors that make frequent INR monitoring impractical
• Patient history of warfarin-associated bleeding events
• CKD with creatinine clearance favoring apixaban pharmacokinetics

The ARISTOTLE trial showed that patients previously naive to vitamin K antagonists derived a larger relative risk reduction from apixaban than warfarin-experienced patients, supporting early initiation of apixaban rather than a warfarin trial. [4] Prescribers should cite this data in step therapy exception requests.

New Jersey's Step Therapy Reform Act (P.L. 2018, c. 23) requires insurers to grant step therapy exceptions within 72 hours (24 hours for urgent cases) when a prescriber certifies that the required drug is contraindicated, clinically ineffective, or likely to cause adverse effects for the specific patient. [10] This law provides a statutory pathway to override a warfarin-first requirement when individualized clinical justification exists.

Dosing Reference for Prescribers and Patients

Getting the dose right matters for both efficacy and safety. The FDA-approved dosing schedule for apixaban varies by indication, and prescribers should verify doses against the current FDA label. [1]

For NVAF stroke prevention, the standard dose is 5 mg orally twice daily. Dose reduction to 2.5 mg twice daily applies when a patient meets at least two of the following three criteria: age 80 years or older, body weight 60 kg or less, serum creatinine 1.5 mg/dL or greater. [1] Underdosing NVAF patients who do not meet these criteria is associated with increased stroke risk and is a documented prescribing error in real-world registry data. [11]

For acute DVT or PE treatment, the dose is 10 mg twice daily for the first 7 days, followed by 5 mg twice daily. For extended VTE prevention beyond 6 months, the dose can be reduced to 2.5 mg twice daily, as validated in the AMPLIFY-EXT trial (N=2,482), which showed a 67% reduction in recurrent VTE versus placebo at this reduced dose without a significant increase in major bleeding. [12]

For DVT prophylaxis after elective hip replacement, the dose is 2.5 mg twice daily for 35 days. After knee replacement, it is 2.5 mg twice daily for 12 days. [1] These durations are fixed and differ from other DOACs; submitting PA requests with the correct indication-specific duration improves approval rates.

How to Get Eliquis Covered or Reduce Your Cost Under Horizon BCBS NJ

Several parallel strategies can reduce or eliminate out-of-pocket costs for commercially insured Horizon members.

Manufacturer Copay Assistance (Bristol-Myers Squibb / Pfizer) The Eliquis 360 Support program offers a copay card for commercially insured patients that limits monthly cost to as little as $10 for up to 24 months of use. [13] Medicare and Medicaid beneficiaries are ineligible for the copay card under federal anti-kickback rules, but they may qualify for the BMS Patient Assistance Foundation or NeedyMeds listings. [14] To activate the card, the patient must have commercial insurance (including Horizon), be a U.S. resident, and not be enrolled in a government-funded plan.

Formulary Exception Request If Eliquis is placed at a higher tier than a clinically comparable alternative, the prescriber can request a formulary exception to have the drug covered at a lower tier. The prescriber must document medical necessity, typically citing the indication, prior treatment history, and relevant guideline support. Horizon's formulary exception form is available on its provider portal, and turnaround is typically 72 hours for standard requests.

Specialty Pharmacy Channels Some Horizon plans direct specialty or high-cost brand medications through a preferred specialty pharmacy network, which may offer different cost-sharing than a retail pharmacy. Checking whether filling at a Horizon-preferred specialty or mail-order pharmacy reduces cost-sharing is worth a phone call to member services (the number on the back of the insurance card).

90-Day Supply at Mail Order Many Horizon plans reduce per-unit cost-sharing when members fill a 90-day supply through CVS Caremark or another contracted mail-order pharmacy rather than a 30-day retail fill. For a chronic indication like NVAF, this is a straightforward way to reduce annual spending on Eliquis.

NJ State Pharmaceutical Assistance Program (PAAD) New Jersey's Pharmaceutical Assistance to the Aged and Disabled (PAAD) program helps eligible seniors and disabled residents cover drug costs not paid by Medicare. [15] Eligibility is income-based; in 2025, the gross income limit is approximately $34,874 for a single person and $42,780 for a married couple, with annual adjustments. Patients who qualify for PAAD may also qualify for the federal Extra Help (Low Income Subsidy) program, which reduces Medicare Part D cost-sharing significantly. [6]

Clinical Context: Why Apixaban Is Often the Preferred DOAC

Apixaban's clinical profile explains why prescribers choose it even when warfarin costs less. Beyond the ARISTOTLE findings on stroke reduction and major bleeding, the AMPLIFY trial (N=5,395) showed apixaban was non-inferior to conventional therapy (enoxaparin plus warfarin) for acute VTE treatment, with a 69% reduction in major bleeding (0.6% vs. 1.8%; P<0.001). [16]

Renal dose adjustment is more forgiving with apixaban than with rivaroxaban or dabigatran. The FDA label supports use down to a creatinine clearance of 15 mL/min and notes that patients on dialysis can receive apixaban at a reduced dose of 5 mg twice daily (or 2.5 mg twice daily if two dose-reduction criteria are met), a population where warfarin's net clinical benefit is debated in the literature. [1] A 2020 JAMA Internal Medicine analysis of Medicare beneficiaries (N=25,523) found apixaban was associated with lower rates of both ischemic stroke and major bleeding compared with warfarin in patients with atrial fibrillation and CKD stages 3 through 5. [17]

Drug interactions are fewer with apixaban than with warfarin. Apixaban is a substrate of CYP3A4 and P-glycoprotein; combined strong inhibitors of both (such as ketoconazole) or combined strong inducers of both (such as rifampin) require dose adjustment or avoidance, but the dietary restrictions and broad drug interaction profile of warfarin do not apply. [1] For patients on polypharmacy regimens, this is a meaningful clinical advantage.

There is no routine monitoring requirement for apixaban. For patients in rural parts of New Jersey or those with limited mobility who find frequent INR clinic visits burdensome, this alone can improve adherence. The AFFIRM trial's data on the relationship between AF burden and stroke risk illustrates why consistent, uninterrupted anticoagulation matters more than dose precision. [18]

What to Do If Horizon BCBS NJ Denies Eliquis Coverage

A denial is not the end of the road. The appeal process has defined steps and statutory timelines in New Jersey.

Step 1: Internal Appeal. Submit a written appeal within 60 days of the denial notice. Include a letter of medical necessity from the prescriber, relevant clinical records, and guideline citations (for example, the 2023 ACC/AHA Class I recommendation for DOACs in NVAF). [3] Horizon must respond within 30 days for standard appeals and 72 hours for urgent appeals under New Jersey law. [8]

Step 2: External Appeal. If the internal appeal is denied, file with a New Jersey-certified IURO. The external reviewer is an independent physician who must make a decision within 30 days (3 days for urgent cases). The insurer is bound by the IURO's decision. [8]

Step 3: NJ DOBI Complaint. If the insurer fails to follow appeal timelines or procedures, file a complaint with the New Jersey Department of Banking and Insurance. DOBI has authority to investigate and sanction insurers for non-compliance. [8]

Step 4: Bridge Therapy or Samples. While an appeal is pending, the prescribing physician can request bridge anticoagulation if clinically urgent and apply for BMS emergency supply through the patient assistance program. The NeedyMeds database lists current eligibility criteria and application links for the BMS Patient Assistance Foundation. [14]

Prescribers who document the NNT and bleeding data from ARISTOTLE [4] and the guideline class of recommendation [3] in their appeal letters generally have a higher rate of approval at the internal appeal stage, based on the documented experience of anticoagulation clinic pharmacists managing these cases.

Apixaban Generic Availability and Future Coverage Outlook

Generic apixaban is expected to reach the U.S. market in mid-2026, following the expiration of pediatric exclusivity and settlement agreements between Bristol-Myers Squibb, Pfizer, and multiple generic manufacturers. [19] The FDA Orange Book lists apixaban under NDA 202155, and several Abbreviated New Drug Applications (ANDAs) are filed and awaiting final approval. [19]

When generic apixaban launches, formulary tier placement will almost certainly shift to Tier 1 or Tier 2 on most Horizon plans, dramatically reducing cost-sharing for new and existing patients. Medicare Part D plans will also be required to cover generic apixaban without a deductible in most circumstances once it achieves preferred generic status. [6] For patients currently managing high cost-sharing or navigating PA requirements, the timeline to generic availability is a concrete reason to maintain coverage continuity rather than discontinue therapy.

The FDA requires generic manufacturers to demonstrate bioequivalence through pharmacokinetic studies; the standard acceptance criterion is a 90% confidence interval for the AUC and Cmax ratios falling within 80% to 125% of the reference listed drug. [20] This means the therapeutic profile of generic apixaban will be clinically equivalent to branded Eliquis.